Abstract
Remarkable efficacy has been achieved in a variety of cancer types by targeting immune checkpoints. The cytotoxic T-lymphocyte–associated antigen 4 inhibitor ipilimumab, the programmed death 1 inhibitors nivolumab and pembrolizumab, and the programmed death ligand 1 inhibitors atezolizumab, avelumab, and durvalumab are the agents currently approved by the US Food and Drug Administration for the treatment of certain advanced malignancies. These agents mark a departure from both standard cytotoxic chemotherapy and targeted therapy. However, they are associated with a unique set of immune-related adverse events (irAEs), which can manifest as a wide range of autoimmune phenomena. The irAEs can affect any system in the body and in rare cases are life-threatening. It is critical for the practicing medical oncologist to recognize and promptly treat any irAEs that may develop.
Original language | English (US) |
---|---|
Pages (from-to) | 364-374 |
Number of pages | 11 |
Journal | Clinical Advances in Hematology and Oncology |
Volume | 16 |
Issue number | 5 |
State | Published - May 2018 |
Keywords
- Immune-related adverse events (irAEs)
- Immunotherapy
- Programmed death 1 (PD-1)
- Programmed death ligand 1 (PD-L1)
ASJC Scopus subject areas
- Hematology
- Oncology